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Dr Joseph Shrager (Stanford, Calif). I appreciate the opportu-
nity to discuss. Mark, very nice paper from what is obviously one
of the most experienced video-assisted thorascopic surgery
(VATS) lobectomy centers and I will not resist the opportunity
to remind you that I am probably—. I think I am the first person
who ever took you through a lobectomy when you were a PGY4
at Penn. Is that right?
Dr Berry. That is right. At Pennsylvania Hospital.520 The Journal of Thoracic and Cardiovascular SurgDr Shrager. So I take pride there.
Moderator. Watch out. That means he’s about to get you.
[laughter]
Dr Shrager. I think it is only natural as you gain more experi-
ence with a newer procedure like VATS lobectomy that unless you
feel there is a compelling reason not to take on tougher tumors that
is what you are going to do. I think you have shown very nicely
with these data that, in your hands at least, in the hands of the
most experienced place in the country, moving to these more chal-
lenging tumors does not increase morbidity and mortality in any
major way anyway, so it is doable if you are very experienced.
The more important question I think is not answered here and
that is: Is there an oncologic reason not to tackle these tumors?
In other words, should we be doing this? I think every survival
analysis that is really scientifically done, published for VATS lo-
bectomy, is focused on stage I tumors, so we do not have any
data yet about survival for stage II and stage III tumors that are
done thoracoscopically and that is what we would need to see to
really answer that second question. My personal bias is that
when we do VATS lobectomies we tend to fragment lymph nodes,
leave little pieces of it stuck to the bronchus—where we would
normally get it out if we were open—and just do, generally,
a less clean job. That is not a problem in cases that eventually prove
to be N0, but I feel very bad when I have done a VATS lobectomy
and the case ends up being N1 or N2. I feel like I have done the
patient a disservice because I might have left a little tiny piece
of something. My hunch is that when we get larger series we are
going to be able to show reduced survival for N1 and N2. So,
my first question is: What is your gut feeling about that statement
that clearance is not quite as good and that might lead to less sur-
vival in the long term?
Dr Berry.Well, I do agree that when you are dissecting the no-
des out thoracoscopically you usually fragment them more than
when you are doing an open procedure, particularly when you
are doing your mediastinal lymph node dissection in level 7 or
4R. My personal feeling is that as long as you are persistent at
clearing out everything that you see, you can do just as good of
a job. We have not looked at the survival of the patients in the
study. We have looked at the survival after thoracoscopic lobec-
tomy and compared it with thoracotomy. We have not published
those results, but the preliminary investigation suggests that the
outcomes are either the same or maybe better after VATS lobec-
tomy. The reason we really have not tried to publish those yet is
we are still trying to make sure that we really do a good job of strat-
ifying the patients and making sure they are matched well because
there really should not be that much of a difference in the long term
between VATS and a thoracotomy approach.
We have had a few papers published by our radiation oncology
colleagues at Duke who have developed models looking at local
recurrences as well as distant failures, and one of the variables
that they have included is a VATS approach. They have never
found that a VATS approach predicts worse outcomes.
Dr Shrager. I suspect that it is so rare that the little fragment of
node you leave behind actually is the malignant fragment that it
would take a huge study to show it. Maybe it really does not matter.
Second question: Do you have information on exactly what
were the causes of conversion to thoracotomy? If they were
done to ensure clearance of nodes in cases when you could notery c February 2013
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Sget the nodes off an important structure, that would be appropriate
and expected, but if they were for bleeding, which is suggested, re-
ally, by the fact that you have increased transfusions in the patients
who were converted, that would be more concerning. Although
you did not show any increased deaths in that group, I am worried
that in less-experienced hands you might have some patients die
from intraoperative hemorrhage.
Dr Berry. I do not know the exact numbers for these patients,
but in previous studies that we have done, probably about half
the conversions are done for bleeding. It can be hard to recreate
the situation retrospectively because most of the time the op
note will be pretty bland in saying bleeding was encountered, so
we converted to thoracotomy. My personal experience with cases
that require conversion as a result of bleeding is that you can con-
trol things pretty well and you can convert and take care of prob-
lems in a very controlled fashion. Most bleeding is from
pulmonary artery branches, which are low pressure and can typi-
cally be controlled with gentle pressure. I think about half the cases
were for bleeding and probably about half the cases were just could
not expose the structures that we wanted to expose or there was
something else that required getting in and being able to palpate
to determine whether something was resectable.
Dr Shrager. Last quick question. Clinically node-positive pa-
tients had double the conversion rate and an increased transfusion
rate. You came short of saying we should not do clinically node-
positive patients.
Dr Berry. I think that if somebody has clinically positive nodes
you should be prepared both to make sure that the patient is pre-
pared for a thoracotomy and, if they are a marginal candidate,
that they would really tolerate that if you think that is going to in-
crease their risk. Despite the increased risk of needing a conver-
sion, most patients who are clinically node positive were still
able to get their procedure done with the thoracoscopic approach.
I would still say that it is okay to start out thoracoscopically, but
just have in mind that there is increased risk that you could run
in to trouble, be ready for it, and just make sure that you were pre-
pared for that beforehand. Our anesthesiologists put epidurals in
all our patients regardless ofwhether it is going to be a thoracotomy
or a thoracoscopic approach. If you use epidurals selectively, then
it might be a good idea that if someone looks like they have PET-
positive nodes, have them get an epidural because there is at least
a higher chance of getting a thoracotomy.
Dr Ross Bremner (Phoenix, Ariz). Thanks very much. Great
paper. When you convert your cases, do you just extend your
4-cm axillary incision and put in a retractor or do you make
another posterolateral thoracotomy incision?
Dr Berry. Most of the cases are just extending the utility inci-
sion. It depends on at what point in the operation there is a conver-
sion. If it is the type of thing where we put the scope in, start to
work around the hilum, and realize that we are not going to be
able to do it thoracoscopically, in those patients we usually just
make a regular posterolateral thoracotomy incision.
Dr Bremner. So posterolateral thoracotomy would be your pre-
ferred approach for a complex operation.
Dr Berry. Yes.
Dr Bremner. I guess my question, then, is: Is there a way that
you could advise people who are learning how to do this procedure
regarding which cases are going to be really hard? For example, isThe Journal of Thoracic and Cathere a size criteria? As we all know, we see tumors that are 6 or 7
cm in size that are mediastinal node negative. I mean, is there a cut-
off in the size? And what about nodal status? I guess from your pa-
per here you infer that if there are clinically node-positive nodes
near the central hilum or near pulmonary arteries, we should prob-
ably just start open?
Dr Berry. Based on what we looked at, I do not think I could
just pick a criteria that would say these cases are going to require
a conversion to thoracotomy. In my experience, and based on the
data, I think the tumors that are node positive are the ones that
are going, most likely, to require a thoracotomy.We tried to stratify
tumor size and see if we could find a size that was going to predict
that you could not do it thoracoscopically and we were not able to.
There were tumors that were 9 cm that were able to be resected
thoracoscopically in the series.
Dr Bremner. If you are taking a 9-cm tumor out of a 4-cm hole,
are you losing the benefit of a VATS lobectomy?
Dr Berry. That is sometimes the hardest part of the case, and it
sometimes requires making the incision bigger, but we still are
able to do the case without any retraction at all, which we think,
ultimately, is probably the reason why people are getting benefit
from this.
Dr Bremner. Thanks very much.
Dr Gary Gelfand (Calgary, Alberta, Canada). An excellent
paper. I was just curious—Your operative times, I mean in the
2 groups<3 cm. Did you have any data on operative time? Because
at what point does increasing operative time make it not necessar-
ily the optimal economic strategy?
Dr Berry. I cannot really answer that. We do not really have
good recordings of operative times in our patient database. Cer-
tainly, the more experienced of the surgeons, their operative times
are less. Operative time also can depend on the level of resident
that is doing the case. In general, we do not use operative time
as one of the criteria to decidewhether to convert to a thoracotomy.
There were a few patients, though, where the op note specifically
said ‘‘Due to failure to progress in the operation, the procedure was
converted to thoracotomy.’’ I can’t really give much more detail on
the operative time other than that.
Dr Steven R. DeMeester (Los Angeles, Calif).Very nice paper.
Just a question. In the patients who have to get converted, do they
lose anything? In other words, have you looked at the patients who
required conversion and compared them with similar patients who
you just started out open? Either in your learning experience, or
whatever, was there a downside to trying a VATS approach in
terms of blood loss or other complications compared with going
straight to an open approach?
Dr Berry.We did not do that. My sense is that the patients who
required a conversion because of bleeding probably had a higher
transfusion rate than if you had just started straight with thoracot-
omy. I do not think that the morbidity of the conversion patients, at
least in our series, was any different than patients who had a thora-
cotomy to start with, at least of what wewould consider significant
complications. Obviously, we would like to avoid transfusions, es-
pecially in these people with lung cancer, but the complications
that they did have were not life-threatening, and most of the
time they did not prolong the patient’s hospital stay. My sense is
that they ultimately did okay, and no worse than if they just started
with a thoracotomy.rdiovascular Surgery c Volume 145, Number 2 521
